Brain and behavior · 2026
Tongxinluo for the Secondary Prevention of Atherosclerotic Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Feng Yanyan, Shi Zhaobo, Zhang Jiewen, Li Jiejie
Аннотация
BACKGROUND: Cardio-cerebrovascular events continue to pose major life-threatening risks worldwide. Though approved for treatment of angina pectoris and ischemic stroke, the effects of tongxinluo, as a traditional Chinese medicine, on stroke and major adverse cardiovascular events (MACE) after atherosclerotic cardiovascular disease (ASCVD) remain controversial.
OBJECTIVE: This study aims to assess the efficacy of tongxinluo in the secondary prevention of ASCVD.
METHODS: The present systematic review was conducted following PRISMA guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. In this study-level meta-analysis, we conducted a comprehensive search of medical libraries and clinical trial registries, spanning from their inception until November 20, 2024, and randomized controlled trials (RCTs) comparing tongxinluo versus no tongxinluo in a secondary prevention. The ASCVD population was included. The primary outcome was stroke and MACE. The secondary outcome was MACE and myocardial infarction.
RESULTS AND CONCLUSION: Four RCTs, including 7087 patients with known coronary artery disease, ischemic stroke, or carotid artery plaque, were included in the analysis. Compared to placebo, tongxinluo numerically decreased the risk of stroke with a RR of 0.84 (95% CI: 0.61-1.17, p = 0.31). For the outcome of MACE, tongxinluo reduced the risk by 28% (RR: 0.72, 95% CI: 0.59-0.88, p = 0.001). Patients randomized to tongxinluo had a RR of 0.70 (95% CI: 0.54-0.92, p = 0.01) for cardiovascular mortality and 0.74 (95% CI: 0.56-0.92, p = 0.01) for all-cause mortality. In summary, in patients with ASCVD, tongxinluo tended to decrease the incidence of stroke, and reduced the composite of stroke, myocardial infarction, and cardiovascular mortality by 28%.
OBJECTIVE: This study aims to assess the efficacy of tongxinluo in the secondary prevention of ASCVD.
METHODS: The present systematic review was conducted following PRISMA guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. In this study-level meta-analysis, we conducted a comprehensive search of medical libraries and clinical trial registries, spanning from their inception until November 20, 2024, and randomized controlled trials (RCTs) comparing tongxinluo versus no tongxinluo in a secondary prevention. The ASCVD population was included. The primary outcome was stroke and MACE. The secondary outcome was MACE and myocardial infarction.
RESULTS AND CONCLUSION: Four RCTs, including 7087 patients with known coronary artery disease, ischemic stroke, or carotid artery plaque, were included in the analysis. Compared to placebo, tongxinluo numerically decreased the risk of stroke with a RR of 0.84 (95% CI: 0.61-1.17, p = 0.31). For the outcome of MACE, tongxinluo reduced the risk by 28% (RR: 0.72, 95% CI: 0.59-0.88, p = 0.001). Patients randomized to tongxinluo had a RR of 0.70 (95% CI: 0.54-0.92, p = 0.01) for cardiovascular mortality and 0.74 (95% CI: 0.56-0.92, p = 0.01) for all-cause mortality. In summary, in patients with ASCVD, tongxinluo tended to decrease the incidence of stroke, and reduced the composite of stroke, myocardial infarction, and cardiovascular mortality by 28%.